Head and neck (H&N) cancers account for about 5% of all malignant tumours. Pain is one of the most feared consequences of H&N neoplasms and is experienced by up to 80% of patients and worsens their quality of life inhibiting speaking, eating, drinking or swallowing. Nevertheless, pain is still often underestimated and undertreated.
Objectives:
The role of opioids in cancer pain has been well established but evidences about the role and the relative effectiveness of opioids such as fentanyl in the context of H&N cancer pain remains unclear.
Methods:
A literature review based on the guidance of the Centre for Reviews and Dissemination was conducted. An iterative approach was used starting with an electronic search in the MEDLINE database. The search terms ((‘Neoplasms’[Mesh]) AND ‘Head and Neck Neoplasms’[Mesh]) AND ‘Fentanyl’[Mesh] were used.
Results:
A total of 18 publications were found by the first performed search on PubMed. Other publications concordant with our aim were found by cross-reference. Considering inclusion and exclusion criteria for our review, eight papers resulted eligible for analysis.
Conclusion:
Fentanyl transdermal therapeutic system (TTS) seems to be an important option, thanks to the way of administration, the good safety and tolerability profiles to control baseline pain. For breakthrough cancer pain (BTcP), several formulations of transmucosal fentanyl are available. All the formulations seem to be active and safety but we lack head-to-head studies of fentanyl versus other strong opioids, as well as with different formulation of fentanyl, particularly for BTcP where H&N cancer population is very poorly represented.
HigginsonIJHearnJMurtaghF. Epidemiology of cancer pain. In: SykesNBennettMIYuanC-S (eds) Clinical pain management: cancer pain, 2nd edn.London: Hodder Arnold, 2008, pp. 13–26.
2.
BernabeiRGambassiGLapaneKet al. Management of pain in elderly patients with cancer: SAGE study group. Systematic assessment of geriatric drug use via epidemiology. JAMA1998; 279(23): 1877–1882.
3.
PortenoyRK. Treatment of cancer pain. Lancet2011; 377(9784): 2236–2247.
4.
Van den Beuken-van EverdingenMHde RijkeJMKesselsAGet al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol2007; 18: 1437–1449.
5.
O’ConnorPBissonJAsplinPet al. Retrospective analysis of self-reporting pain scores and pain management during head and neck IMRT radiotherapy: a single institution experience. Radiography2017; 23(2): 103–106.
6.
BaxiSFuryMGanlyIet al. Ten years of progress in head and neck cancers. J Natl Compr Canc Netw2012; 10(7): 806–810.
7.
EltingLSKeefeDMSonisSTet al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer2008; 113(10): 2704–2713.
8.
TrottiABellmLAEpsteinJBet al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol2003; 66: 253–262.
9.
SchindlerADenaroNRussiEGet al. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol2015; 96(2): 372–384.
10.
YazbeckVYVillaruzLHaleyMet al. Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Cancer J2013; 19(3): 231–237.
11.
ArmstrongJAMcCaffreyR. The effects of mucositis on quality of life in patients with head and neck cancer. Clin J Oncol Nurs2005; 10: 53–56.
12.
GrondSZechDSchugSAet al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage1991; 6(7): 411–422.
13.
World Health Organization. Cancer pain relief, 2nd edn.Geneva: World Health Organization, 1996.
14.
CarlsonCL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. J Pain Res2016; 9: 515–534.
15.
KestenbaumMGVilchesAOMessersmithSet al. Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med2014; 15(7): 1129–1153.
16.
PortenoyRKHagenNA. Breakthrough pain: definition, prevalence and characteristics. Pain1990; 41(3): 273–281.
17.
MercadanteS. Pharmacotherapy for breakthrough cancer pain. Drugs2012; 72: 181–190.
18.
BhatnagarSUpadhyaySMishraS. Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. J Palliat Med2010; 13: 291–295.
19.
CaraceniAHanksGKaasaSet al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol2012; 13(2): e58–e68.
20.
RipamontiCISantiniDMaranzanoEet al. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol2012; 23(suppl 7): vii139–vii154.
21.
BenedettiCBrockCCleelandCet al. NCCN practice guidelines for cancer pain. Oncology2000; 14(11A): 135–150.
22.
HessRStieblerGHerzA. Pharmacokinetics of fentanyl in man and the rabbit. Eur J Clin Pharmacol1972; 4(3): 137–141.
23.
FallonMRealeCDaviesAet al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol2011; 9: 224–231.
24.
GourlayGKKowalskiSRPlummerJLet al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain1990; 40(1): 21–28.
25.
MiserAW1NarangPKDothageJAet al. Transdermal fentanyl for pain control in patients with cancer. Pain1989; 37: 15–21.
26.
AlbertsDSSmithCCParikhNet al. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. Pain Manag2016; 6(5): 427–434.
27.
MercadanteSPortenoyRK. Breakthrough cancer pain: twenty-five years of study. Pain2016; 157(12): 2657–2663.
28.
SchugSATingS. Fentanyl formulations in the management of pain: an update. Drugs2017; 77(7): 747–763.
29.
MystakidouKKatsoudaEParpaEet al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care2005; 22: 228–232.
30.
Systematic reviews: CRD’s guidance for undertaking reviews in healthcare. York: Centre for Reviews and Dissemination, 2009.
31.
HigginsonIJGaoW. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol2012; 30: 4373–4379.
32.
GrondSZechDLehmannKAet al. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain1997; 69: 191–198.
33.
HaumannJGeurtsJWvan KuijkSMet al. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. Eur J Cancer2016; 65: 121–129.
34.
ChangJTLinCYLinJCet al. Transdermal fentanyl for pain caused by radiotherapy in head and neck cancer patients treated in an outpatient setting: a multicenter trial in Taiwan. Jpn J Clin Oncol2010; 40(4): 307–312.
35.
GuoSPWuSGZhouJet al. Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life. Drug Des Devel Ther2014; 12(8): 497–503.
36.
Konopka-FilippowMZabrockaEWójtowiczAet al. Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience. Int Dent J2015; 65(5): 242–248.
37.
SimonSMSchwartzbergLS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manage2014; 10: 207–215.
38.
ChangARoelandEJAtayeeRSet al. Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care. J Pain Palliat Care Pharmacother2015; 29(3): 247–260.
39.
PignonTFernandezLAyassoSet al. Impact of radiation oncology practice on pain: a cross-sectional survey. Int J Radiat Oncol Biol Phys2004; 60: 1204–1210.
40.
D’AmbrosioDJLiTHorwitzEMet al. Does treatment interruption affect outcome after radiotherapy for prostate cancer?Int J Radiat Oncol Biol Phys2008; 72: 1402–1407.
41.
KwongDLShamJSChuaDTet al. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys1997; 39: 703–710.
42.
MazzolaRRicchettiFFiorentinoAet al. Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. Clin Transl Oncol2017; 19(5): 593–598.
43.
BossiPLocatiLBergaminiCet al. Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. Oral Oncol2014; 50(9): 884–887.
44.
MercadanteSMarchettiPCuomoAet al. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer2016; 24(2): 961–968.
45.
MercadanteSAdileCCuomoAet al. Fentanyl buccal tablet vs. oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manage2015; 50(5): 579–586.
